


thiadiazolyl, pyrrolyl, and pyrimidyl, all of which can be optionally substituted with one, two, or three substituents from the group consisting of: C₁-C₆alkyl, C₁-C₆alkoxy, (CH₂)₀₋₅CO₂R₁, C(O)N(R₁)₂, CN, (CH₂)₀₋₅OH, NO₂, F, Cl, Br, I, CF₃, N(R₁)₂, and NHC(O)R₁; A is C(O)NHOH or N(CHO)OH;

X is NH, when Y is C(O), or X is CH₂ when Y is C(O) or CH₂; or a pharmaceutically acceptable salt thereof.

5. (New) A compound according to Formula (I):



wherein

R₁ is selected from the group consisting of C₁-C₉alkyl, C₁-₂alkylAr, and Ar;

R₂ is selected from the group consisting of hydrogen, C₁-C₉alkyl, phenyl, C₁-₄alkylAr', NHR₄, NHC(O)R₄, C₂-₄alkylNR₃R₄, C₁-₃alkylC(O)NR₃R₄, C₁-₃alkylC(O)Ar', C₂-₃alkylNHC(O)NR₃R₄, C₂-₃alkylNHC(O)Ar', and C₁-₂alkylSO₂R₄;

R₃ is selected from the group consisting of H, C₁-C₉alkyl, C₁-₂alkylAr, and Ar;

R₄ is R₃, Ar', or R₄ may be taken together with R₃ and the nitrogen atom to which they are attached to form a heterocyclic ring which is optionally substituted with one, two, or three substituents each independently selected from the group consisting of C₁-₃alkyl, aryl, C₁-₃alkoxy (optionally substituted by one to three F), aryloxy, carboxy, oxo, hydroxy, amino, nitro, and cyano, or which may be optionally fused to an aryl, a heteroaryl, or a second heterocyclic ring;

Ar is selected from the group consisting of phenyl, furyl, and thienyl, all of which can be optionally substituted with one, two, or three substituents each independently selected from the group consisting of: C₁-C₃alkyl, CN, F, Cl, Br, and I;

Ar' is selected from the group consisting of: phenyl, naphthyl, biphenyl, furyl, pyridyl, thienyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, tetrazolyl, imidazolyl, imidazolidinyl, benzofuranyl, 1-benzo[b]thiophenyl, indolyl, thiazolidinyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, and pyrimidyl, all of which can be optionally substituted with one, two, or three substituents each independently selected from the group consisting of: C₁-C₆alkyl, C₁-C₆alkoxy, (CH₂)₀₋₅CO₂R₁, C(O)N(R₁)₂, CN, (CH₂)₀₋₅OH, NO₂, F, Cl, Br, I, CF₃, N(R₁)₂, and NHC(O)R₁;

A is N(CHO)OH;

X is NH, when Y is C(O), or X is CH₂ when Y is C(O) or CH₂; or a pharmaceutically acceptable salt thereof.

6. (New) A compound according to claim 5, wherein the pharmaceutically acceptable salt is a hydrochloride, hydrobromide, trifluoroacetate, sodium, potassium, or magnesium salt.

7. (New) A compound according to claim 5 selected from the group consisting of:

N-[(S)-1-Benzyl-4-pentyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-1,4-Dibenzyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-1-Benzyl-4-butyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-2,5-Dioxo-4-pentyl-1-phenyl-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-4-Butyl-1-(3,4-dichloro-benzyl)-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-4-Butyl-2,5-dioxo-1-(2-oxo-2-phenyl-ethyl)-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-1-Biphenyl-4-ylmethyl-4-butyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-1-Benzyl-4-cyclohexylmethyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-4-Butyl-1-[2-(5-chloro-3-methyl-1-benzo[b]thiophen-2-yl)-2-oxo-ethyl]-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

2-[(S)-4-Butyl-4-[(formyl-hydroxy-amino)methyl]-2,5-dioxo-

imidazolidin-1-yl}-N-(3,5-dichlorophenyl)acetamide;

2-{(S)-4-Butyl-4-[(formylhydroxyamino)methyl]-2,5-dioxo-imidazolidin-1-ylmethyl}benzoic acid methyl ester;

N-[(S)-4-Butyl-1-(2-morpholin-4-yl-ethyl)-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide;

N-[(S)-1-(2-Benzofuran-2-yl-2-oxo-ethyl)-4-butyl-2,5-dioxo-imidazolidin-4-ylmethyl]-N-hydroxyformamide; and

2-{(S)-4-Butyl-4-[(formylhydroxyamino)methyl]-2,5-dioxo-imidazolidin-1-ylmethyl}benzoic acid;

and pharmaceutically acceptable salts thereof.

8. (New) A method of treating a bacterial infection comprising administering to a subject in need of treatment a compound according to claim 7, or pharmaceutically acceptable salt thereof.

9. (New) A pharmaceutical composition comprising a compound according to claim 7, or a pharmaceutically acceptable salt thereof, in admixture with one or more physiologically acceptable carriers or excipients.

10. (New) A compound according to claim 7, wherein the pharmaceutically acceptable salt is a hydrochloride, hydrobromide, trifluoroacetate, sodium, potassium, or magnesium salt.

11. (New) A pharmaceutical composition comprising a compound according to claim 5, or a pharmaceutically acceptable salt thereof, in admixture with one or more physiologically acceptable carriers or excipients.